Toronto, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, a Toronto-based drug development company, has entered into a new strategic partnership with Celgene Corporation. The focus of the collaboration will be on a pre-clinical therapeutic developed by the Ontario Institute for Cancer Research (OICR) for the treatment of leukemia and other blood cancers, specifically targeting the WDR5 protein.
Under the terms of the agreement, Celgene has the option to acquire TRPH-395 from Triphase Accelerator. Celgene will pay an upfront amount of ...
Toronto-based MaRS Innovation announced today that one of its leading portfolio companies, Triphase Accelerator Corporation (Triphase), has agreed to sell assets relating to its first investigational compound, marizomib (MRZ) to U.S.-based Celgene Corporation, through an affiliate, for an undisclosed amount. Marizomib is the first major divestiture of a compound developed inside a MaRS Innovation portfolio company.
Triphase was established by MaRS Innovation in partnership with the Ontario Institute for Cancer Research (OICR) and MaRS Discovery District, with a single powerful mandate of ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published the following guest column by Dr. Raphael Hofstein, MaRS Innovation’s president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
There’s a historical trend in Canadian culture with far-reaching effects for the way we do business, ranging from entertainment to academia to science. Namely, it’s that until quite recently, Canadians weren’t into cultivating national star systems. 
As Gideon Hayden recently wrote for TechCrunch, if you’re a Canadian tall poppy ...
Agreement signed as part of Ontario's life sciences trade mission to Israel
TEL AVIV and TORONTO (May 16, 2016) – BioLineRx Ltd. a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for 15 of Toronto's top academic institutions.
Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of start-up companies originating from MaRS Innovation's members to identify in-licensing, co-development or other ...
TORONTO and SAN DIEGO (December 8, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that positive results from its ongoing Phase 1 proof-of-concept study evaluating marizomib in patients with relapsed and refractory multiple myeloma will be presented at the 57th Annual Meeting of the American Society of Hematology (ASH).
The company will also present preclinical data on marizomib demonstrating synergistic activity in combination with pomalidomide. Marizomib is a novel ...
TORONTO and SAN DIEGO (November 19, 2015) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma.
Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease's poor prognosis. Triphase is evaluating marizomib, a novel and highly ...
TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook Health Sciences Centre, a MaRS Innovation member institution. MaRS Innovation is also a Triphase investor.
Under the agreement, SRI will assist in the development of Triphase’s novel, first-in-class, fully human bi-specific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR ...
Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, announced October 27, 2014 new and expanded strategic collaborations with Celgene Corporation.
This announcement was covered in Genetic Engineering and Biotechnology News (GEN), BioCentury Extra (no link available), Pharmaceutical Business Review (no link available), Scrip and BioWorld Today (no link available). It builds on Triphase's original collaborative agreement with Celgene in January 2014.
The company has also announced a new global license for a fully human, bi-specific ...
Dr. Shana Kelley, co-founder of Xagenic Inc. and a professor of biochemistry at the University of Toronto, has been named to the Globe and Mail's Top 12 Canadian Innovators list.
The contest solicited nominations from across Canada that were assessed by a panel of judges. According to the Globe, the contest "recognizes talented Canadians who not only have great ideas, but also turn them into reality."
Here's an excerpt:
Another innovator who is taking on the traditional way of doing things is Ms. Kelley, ...